Back to Agenda
Session 1: A Year in Review of Advancing RWE Globally
Session Chair(s)
Keri Monda, PhD, MS
Executive Director, Center for Observational Research
Amgen, United States
Rachele Hendricks-Sturrup, DrSc, MA, MSc
Research Director, Real-World Evidence
Duke-Margolis Institute For Health Policy, United States
Over the past year, global regulatory bodies have released pivotal guidance and launched key initiatives shaping the future of Real-World Evidence (RWE). This session will feature updates on EMA’s DARWIN EU activities, FDA’s latest guidance and submissions involving real-world data (RWD), and progress on ICH M14. Panelists will also highlight the publication of new RWE-related standards and their implications for regulatory and payer decision-making. Insights will focus on how these developments are influencing industry strategies and evidence generation practices.
Learning Objective : - Discuss key 2024 RWE milestones from global regulators including EMA, FDA, and ICH
- Interpret new standards and guidance shaping the regulatory and payer use of RWE
- Examine how recent regulatory developments are shaping industry approaches to evidence generation and submission
Speaker(s)
Speaker
Robert Reynolds, DrSc, MSc, FISPE
GSK, United States
Vice President, Global Epidemiology, CMO, R&D
Speaker
Dan Riskin, MD
Verantos, United States
Founder and Chief Executive Officer
Speaker
Hidetaka Kobayashi, MPH
Pharmaceuticals and Medical Devices Agency (PMDA) Office of Drug Safety I, Japan
Have an account?